Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition

The Lancet

Volumn 391, Issue 10126, 2018, Pages 1224-1236

  Prabhakaran, Dorairaj ^a,b,c,d   Anand, Shuchi ^e   Watkins, David ^f   Gaziano, Thomas ^g   Wu, Yangfeng ^h   Mbanya, Jean Claude ⁱ   Nugent, Rachel ^j   Ajay, Vamadevan S ^k   Afshin, Ashkan ^k   Adler, Alma ^k   Ali, Mohammed K ^k   Bateman, Eric ^k   Bettger, Janet ^k   Bonow, Robert O ^k   Brouwer, Elizabeth ^k   Bukhman, Gene ^k   Bull, Fiona ^k   Burney, Peter ^k   Capewell, Simon ^k   Chan, Juliana ^k   Chandrasekar, Eeshwar K ^k   Chen, Jie ^k   Criqui, Michael H ^k   Dirks, John ^k   Dugani, Sagar B ^k   Engelgau, Michael ^k   El Nahas, Meguid ^k   Fall, Caroline HD ^k   Feigin, Valery ^k   Fowkes, F Gerald R ^k   Glassman, Amanda ^k   Goenka, Shifalika ^k   Gupta, Rajeev ^k   Hasan, Babar ^k   Hersch, Fred ^k   Hu, Frank ^k   Huffman, Mark D ^k   Jabbour, Samer ^k   Jarvis, Deborah ^k   Jeemon, Panniyammakal ^k   Joshi, Rohina ^k   Kamano, Jemima H ^k   Kengne, Andre Pascal ^k   Kudesia, Preeti ^k   Kumar, R Krishna ^k   Kumaran, Kalyanaraman ^k   Lambert, Estelle V ^k   Lee, Edward S ^k   Li, Chaoyun ^k   Luo, Rong ^k   Magee, Matthew ^k   Malik, Vasanti S ^k   Marin Neto, J Antonio ^k   Marks, Guy ^k   Mayosi, Bongani ^k   McGuire, Helen ^k   Micha, Renata ^k   Miranda, J Jaime ^k   Montoya, Pablo Aschner ^k   Moran, Andrew E ^k   Mozaffarian, Dariush ^k   Naicker, Saraladevi ^k   Naidoo, Nadraj G ^k   Narayan, KM Venkat ^k   Nikolic, Irina ^k   O'Donnell, Martin ^k   Onen, Churchill ^k   Osmond, Clive ^k   Patel, Anushka ^k   Perez Padilla, Rogelio ^k   Poulter, Neil ^k   Pratt, Michael ^k   Rabkin, Miriam ^k   Rajan, Vikram ^k   Rassi, Anis ^k   Rawal, Ishita ^k   Remuzzi, Giuseppe ^k   Riella, Miguel ^k   Roth, Greg A ^k   Roy, Ambuj ^k   Rubinstein, Adolfo ^k   Sakuma, Yuna ^k   Sampson, Uchechukwu KA ^k   Siegel, Karen R ^k   Sliwa, Karen ^k   Suhrcke, Marc ^k   Tandon, Nikhil ^k   Thomas, Bernadette ^k   Vaca, Claudia ^k   Vedanthan, Rajesh ^k   Verguet, Stéphane ^k   Webb, Michael ^k   Weber, Mary Beth ^k   Whitsel, Laurie ^k   Wong, Gary ^k   Yan, Lijing L ^k   Yancy, Clyde W ^k   Zhang, Ping ^k   Zhao, Dong ^k   Zhu, Yishan ^k   more..

^a PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^b Centre for chronic disease control (CoE CARRS)   (India)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d EMORY UNIVERSITY   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

ⁱ UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^j RTI INTERNATIONAL   (United States)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUDGET; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CAUSE OF DEATH; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISABILITY; HEALTH CARE QUALITY; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; MORTALITY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; STRATEGIC PLANNING; DEVELOPING COUNTRY; HEALTH CARE PLANNING;

CARDIOVASCULAR DISEASES; DEVELOPING COUNTRIES; HEALTH PRIORITIES; HUMANS; RESPIRATORY TRACT DISEASES;

EID: 85032836840     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32471-6     Document Type: Review

References (99)

1. WHO. Global health estimates 2015: deaths by cause, age, sex, by country and by region, 2000–2015. 2017, World Health Organization, Geneva.
2. UN General Assembly. High-level meeting on prevention and control of non-communicable diseases. 2011 New York; Sept 19–20.
3. WHO. Global health observatory data for 2012. 2012, World Health Organization, Geneva.
4. Gelband, H, Sankaranarayanan, R, Gauvreau, CL, et al. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities. Lancet 387 (2016), 2133–2144 3rd edition.
5. Patel, V, Chisholm, D, Parikh, R, et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities. Lancet 387 (2016), 1672–1685 3rd edition.
6. Camargo, CAJ, Rachelefsky, G, Schatz, M, Managing asthma exacerbations in the emergency department: summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. J Allergy Clin Immunol 124:suppl 2 (2009), S5–14.
7. WHO. Global health and ageing. 2011, World Health Organization, Geneva.
8. Roth, GA, Forouzanfar, MH, Moran, AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 372 (2015), 1333–1341.
9. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1603–1658.
10. Yusuf, S, Rangarajan, S, Teo, K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 371 (2014), 818–827.
11. Manson, JE, Willett, WC, Stampfer, MJ, et al. Body weight and mortality among women. N Engl J Med 333 (1995), 677–685.
12. van den Hoogen, PC, Feskens, EJ, Nagelkerke, NJ, Menotti, A, Nissinen, A, Kromhout, D, The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 342 (2000), 1–8.
13. Yusuf, S, Hawken, S, Ounpuu, S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004), 937–952.
14. Sposato, LA, Saposnik, G, Gross domestic product and health expenditure associated with incidence, 30-day fatality, and age at stroke onset: a systematic review. Stroke 43 (2012), 170–177.
15. Jaspers, L, Colpani, V, Chaker, L, et al. The global impact of non-communicable diseases on households and impoverishment: a systematic review. Eur J Epidemiol 30 (2015), 163–188.
16. Huffman, MD, Rao, KD, Pichon-Riviere, A, et al. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One, 6, 2011, e20821.
17. Niens, LM, Cameron, A, Van de Poel, E, Ewen, M, Brouwer, WB, Laing, R, Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med, 7, 2010, e10000333.
18. Britton, J, Progress with the global tobacco epidemic. Lancet 385 (2015), 924–926.
19. WHO. Noncommunicable diseases and mental health: about 9 voluntary global targets. 2014 http://www.who.int/nmh/ncd-tools/definition-targets/en/ (accessed March 10, 2017).
20. WHO. Tobacco free initiative (TFI). 2017 http://www.who.int/tobacco/mpower/en/ (accessed July 12, 2017).
21. Bilano, V, Gilmour, S, Moffiet, T, et al. Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. Lancet 385 (2015), 966–976.
22. Jha, P, Peto, R, Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 370 (2014), 60–68.
23. Verguet, S, Gauvreau, CL, Mishra, S, et al. The consequences of tobacco tax on household health and finances in rich and poor smokers in China: an extended cost-effectiveness analysis. Lancet Glob Health 3 (2015), e206–e216.
24. WHO. WHO technical manual on tobacco tax administration. 2010, World Health Organization, Geneva.
25. Lamprecht, B, McBurnie, MA, Vollmer, WM, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 139 (2011), 752–763.
26. Salvi, SS, Barnes, PJ, Chronic obstructive pulmonary disease in non-smokers. Lancet 374 (2009), 733–743.
27. Hallal, PC, Andersen, LB, Bull, FC, et al. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 380 (2012), 247–257.
28. The Institute for Health Metrics and Evaluation. GBD data visualizations. 2013, Institute for Health Metrics and Evaluation, Seattle.
29. Heath, GW, Parra, DC, Sarmiento, OL, et al. Evidence-based intervention in physical activity: lessons from around the world. Lancet 380 (2012), 272–281.
30. Wang, Y, Cai, L, Wu, Y, et al. What childhood obesity prevention programmes work? A systematic review and meta-analysis. Obes Rev 16 (2015), 547–565.
31. Conn, VS, Hafdahl, AR, Cooper, PS, Brown, LM, Lusk, SL, Meta-analysis of workplace physical activity interventions. Am J Prev Med 37 (2009), 330–339.
32. Laine, J, Kuvaja-Kollner, V, Pietila, E, Koivuneva, M, Valtonen, H, Kankaanpaa, E, Cost-effectiveness of population-level physical activity interventions: a systematic review. Am J Health Promot 29 (2014), 71–80.
33. Pauwels, RA, Pedersen, S, Busse, WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 361 (2003), 1071–1076.
34. Collins, R, Reith, C, Emberson, J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388 (2016), 2532–2561.
35. Sprint Research Group, Wright, JT Jr, Williamson, JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
36. Chow, CK, Teo, KK, Rangarajan, S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310 (2013), 959–968.
37. Poulter, NR, Prabhakaran, D, Caulfield, M, Hypertension. Lancet 386 (2015), 801–812.
38. Correa, CM, Implications of bilateral free trade agreements on access to medicines. Bull World Health Organ 84 (2006), 399–404.
39. Bradford, Kerry V, Lee, K, TRIPS, the Doha Declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?. Glob Health, 3, 2007, 3.
40. Lybecker, KM, Fowler, E, Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules. J Law Med Ethics 37 (2009), 222–239.
41. Kaplan, WA, Wirtz, VJ, Stephens, P, The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis. PLoS One, 8, 2013, e74399.
42. Ait-Khaled, N, Auregan, G, Bencharif, N, et al. Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis 4 (2000), 268–271.
43. WHO. Essential medicines and health products: WHO model lists of essential medicines. 2017 http://www.who.int/medicines/publications/essentialmedicines/en/ (accessed July 25, 2017).
44. Cohen, D, Carter, P, How small changes led to big profits for insulin manufacturers. BMJ, 341, 2010, c7139.
45. Yusuf, S, Islam, S, Chow, CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378 (2011), 1231–1243.
46. Liyanage, T, Ninomiya, T, Jha, V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385 (2015), 1975–1982.
47. Anand, S, Bitton, A, Gaziano, T, The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS One, 8, 2013, e72860.
48. Braimoh, RW, Mabayoje, MO, Amira, CO, Bello, BT, Microbial quality of hemodialysis water, a survey of six centers in Lagos, Nigeria. Hemodial Int 18 (2014), 148–152.
49. Grimaldi, A, Ammirati, E, Karam, N, et al. Cardiac surgery for patients with heart failure due to structural heart disease in Uganda: access to surgery and outcomes. Cardiovasc J Afr 25 (2014), 204–211.
50. Sakuma, Y, Glassman, A, Vaca, C, Chapter 21. Prabhakaran, D, Gaziano, T, Anand, S, Mbanya, J-C, Wu, Y, Nugent, R, (eds.) Disease control priorities, 3rd edn, 2017, World Bank, Washington DC Volume 5: cardiovascular, respiratory, and related disorders, (in press).
51. Gaziano, T, Suhrcke, M, Brouwer, E, Levin, C, Nikolic, I, Nugent, R, Chapter 19. Prabhakaran, D, Gaziano, T, Anand, S, Mbanya, J-C, Wu, Y, Nugent, R, (eds.) Disease control priorities, 3rd edn., 2017, World Bank, Washington, DC Volume 5: cardiovascular, respiratory, and related disorders, (in press).
52. Brouwer, ED, Watkins, D, Olson, Z, Goett, J, Nugent, R, Levin, C, Provider costs for prevention and treatment of cardiovascular and related conditions in low- and middle-income countries: a systematic review. BMC Public Health, 15, 2015, 1183.
53. Shroufi, A, Chowdhury, R, Anchala, R, et al. Cost effective interventions for the prevention of cardiovascular disease in low and middle income countries: a systematic review. BMC Public Health, 13, 2013, 285.
54. Suhrcke, M, Boluarte, TA, Niessen, L, A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries. BMC Public Health, 12, 2012, 2.
55. Nakhimovsky, SS, Feigl, AB, Avila, C, O'Sullivan, G, Macgregor-Skinner, E, Spranca, M, Taxes on sugar-sweetened beverages to reduce overweight and obesity in middle-income countries: a systematic review. PLoS One, 11, 2016, e0163358.
56. Colchero, MA, Popkin, BM, Rivera, JA, Ng, SW, Beverage purchases from stores in Mexico under the excise tax on sugar sweetened beverages: observational study. BMJ, 352, 2016, h6704.
57. Ding, D, Lawson, KD, Kolbe-Alexander, TL, et al. The economic burden of physical inactivity: a global analysis of major non-communicable diseases. Lancet 388 (2016), 1311–1324.
58. Meng, L, Xu, H, Liu, A, et al. The costs and cost-effectiveness of a school-based comprehensive intervention study on childhood obesity in China. PLoS One, 8, 2013, e77971.
59. Ali, MK, Siegel, KR, Chandrasekar, E, et al. Chapter 12. Prabhakaran, D, Gaziano, T, Anand, S, Mbanya, J-C, Wu, Y, Nugent, R, (eds.) Disease control priorities, 3rd edn, 2017, World Bank, Washington, DC Volume 5: cardiovascular, respiratory, and related disorders, (in press).
60. Diaz de Leon-Castaneda, C, Altagracia-Martinez, M, Kravzov-Jinich, J, Cardenas-Elizalde, Mdel R, Moreno-Bonett, C, Martinez-Nunez, JM, Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City. Clinicoecon Outcomes Res 4 (2012), 57–65.
61. Gaede, P, Valentine, WJ, Palmer, AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 31 (2008), 1510–1515.
62. Ali, MK, Singh, K, Kondal, D, et al. Effectiveness of a multicomponent quality improvement strategy to improve achievement of diabetes care goals: a randomized, controlled trial. Ann Intern Med 165 (2016), 399–408.
63. Habib, SH, Biswas, KB, Akter, S, Saha, S, Ali, L, Cost-effectiveness analysis of medical intervention in patients with early detection of diabetic foot in a tertiary care hospital in Bangladesh. J Diabetes Complications 24 (2010), 259–264.
64. Rachapelle, S, Legood, R, Alavi, Y, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology 120 (2013), 566–573.
65. Araújo, DV, Tura, BR, Basileiro, AL, et al. Custo-efetividade da trombólise pré-hospitalar vs intra-hospitalar no infarto agudo do miocárdio. Arq Bras Cardiol 90 (2008), 100–107.
66. Sritipsukho, P, Riewpaiboon, A, Chaiyawat, P, Kulkantrakorn, K, Cost-effectiveness analysis of home rehabilitation programs for Thai stroke patients. J Med Assoc Thai 93:suppl 7 (2010), S262–S270.
67. Ministry of Health. Guidelines on clinical and programmatic management of major non communicable diseases. 2016, Federal Democratic Republic of Ethiopia, Addis Ababa.
68. Watkins, DA, Johnson, CO, Colquhoun, SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med 377 (2017), 713–722.
69. Alegre-Díaz, J, Herrington, W, López-Cervantes, M, et al. Diabetes and cause-specific mortality in Mexico city. N Engl J Med 375 (2017), 1961–1972.
70. WHO. Global action plan for the prevention and control of noncommunicable diseases. 2013, World Health Organization, Geneva.
71. Mock, C, Kobusingye, O, Nugent, R, Smith, KR, Disease control priorities. Volume 7: Injury prevention and environmental health, 3rd edn, 2017, World Bank, Washington, DC (in press).
72. WHO. From burden to “best buys”: reducing the economic impact of non-communicable diseases in low- and middle-income countries. 2011, World Health Organization, Geneva.
73. Webster, JL, Dunford, EK, Hawkes, C, Neal, BC, Salt reduction initiatives around the world. J Hypertens 29 (2011), 1043–1050.
74. Restrepo, BJ, Rieger, M, Denmark's policy on artificial trans fat and cardiovascular disease. Am J Prev Med 50 (2016), 69–76.
75. Afshin, A, Micha, R, Webb, M, et al. Chapter 6. Prabhakaran, D, Gaziano, T, Anand, S, Mbanya, J-C, Wu, Y, Nugent, R, (eds.) Disease control priorities, 3rd edn, 2017, World Bank, Washington, DC Volume 5: cardiovascular, respiratory, and related disorders., (in press).
76. Bull, F, Goenka, S, Lambert, V, Pratt, M, Chapter 5. Prabhakaran, D, Gaziano, T, Anand, S, Mbanya, J-C, Wu, Y, Nugent, R, (eds.) Disease control priorities, 3rd edn., 2017, World Bank, Washington, DC Volume 5: cardiovascular, respiratory, and related disorders., (in press).
77. Mock, CN, Kobusingye, O, Nugent, R, Smith, KR, Disease control priorities. Volume 7: injury prevention and environmental health, 3rd edn, 2017, World Bank, Washington, DC (in press).
78. Gaziano, TA, Abrahams-Gessel, S, Denman, CA, et al. An assessment of community health workers' ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in Bangladesh, Guatemala, Mexico, and South Africa: an observational study. Lancet Glob Health 3 (2015), e556–e563.
79. Jafar, TH, Islam, M, Hatcher, J, et al. Community based lifestyle intervention for blood pressure reduction in children and young adults in developing country: cluster randomised controlled trial. BMJ, 340, 2010, c2641.
80. Falbe, J, Thompson, HR, Becker, CM, Rojas, N, McCulloch, CE, Madsen, KA, Impact of the Berkeley excise tax on sugar-sweetened beverage consumption. Am J Public Health 106 (2016), 1865–1871.
81. Cecchini, M, Sassi, F, Lauer, JA, Lee, YY, Guajardo-Barron, V, Chisholm, D, Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet 376 (2010), 1775–1784.
82. Gaziano, T, Abrahams-Gessel, S, Surka, S, et al. Cardiovascular disease screening by community health workers can be cost-effective in low-resource countries. Health Aff 34 (2015), 1538–1545.
83. Ajay, VS, Jindal, D, Roy, A, et al. Development of a smartphone-enabled hypertension and diabetes mellitus management package to facilitate evidence-based care delivery in primary healthcare facilities in India: the mPower heart project. J Am Heart Assoc, 5, 2016, e004343.
84. Gaziano, TA, Pagidipati, N, Scaling up chronic disease prevention interventions in lower- and middle-income countries. Annu Rev Public Health 34 (2013), 317–335.
85. Lonn, E, Yusuf, S, Polypill: the evidence and the promise. Curr Opin Lipidol 20 (2009), 453–459.
86. WHO. Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. 2010, World Health Organization, Geneva.
87. Gaziano, TA, Cardiovascular disease in the developing world and its cost-effective management. Circulation 112 (2005), 3547–3553.
88. Bateman, ED, Hurd, SS, Barnes, PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31 (2008), 143–178.
89. Self, TH, Usery, JB, Howard-Thompson, AM, Sands, C, Asthma treatment protocols in the emergency department: are they effective?. J Asthma 44 (2007), 243–248.
90. Teerawattananon, Y, Mugford, M, Tangcharoensathien, V, Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health 10 (2007), 61–72.
91. Praditpornsilpa, K, Lekhyananda, S, Premasathian, N, et al. Prevalence trend of renal replacement therapy in Thailand: impact of health economics policy. J Med Assoc Thai 94:suppl 4 (2011), S1–S6.
92. Tantivess, S, Werayingyong, P, Chuengsaman, P, Teerawattananon, Y, Universal coverage of renal dialysis in Thailand: promise, progress, and prospects. BMJ, 346, 2013, f462.
93. Reddy, NS, Kappanayil, M, Balachandran, R, et al. Preoperative determinants of outcomes of infant heart surgery in a limited-resource setting. Semin Thorac Cardiovasc Surg 27 (2015), 331–338.
94. Medina-Pestana, JO, Organization of a high-volume kidney transplant program—the “assembly line” approach. Transplantation 81 (2006), 1510–1520.
95. Axelrod, DA, Guidinger, MK, McCullough, KP, Leichtman, AB, Punch, JD, Merion, RM, Association of center volume with outcome after liver and kidney transplantation. Am J Transplant 4 (2004), 920–927.
96. Wang, M, Moran, AE, Liu, J, et al. Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. Circ Cardiovasc Qual Outcomes 7 (2014), 78–85.
97. Khan, T, Bertram, MY, Jina, R, Mash, B, Levitt, N, Hofman, K, Preventing diabetes blindness: cost effectiveness of a screening programme using digital non-mydriatic fundus photography for diabetic retinopathy in a primary health care setting in South Africa. Diabetes Res Clin Pract 101 (2013), 170–176.
98. Ribeiro, RA, Stella, SF, Zimerman, LI, Pimentel, M, Rohde, LE, Polanczyk, CA, Cost-effectiveness of implantable cardioverter defibrillators in Brazil in the public and private sectors. Arq Bras Cardiol 95 (2010), 577–586.
99. Nugent, R, Kelly, BB, Narula, J, An evolving approach to the global health agenda: countries will lead the way on NCD prevention and control. Glob Heart 7 (2012), 3–6.